CNBC October 11, 2024
Jessica Dickler

Key Points

– About 165 million Americans rely on employer-sponsored health insurance, and yet workers may still not get the coverage they want — particularly when it comes to drugs such as Wegovy and Ozempic.

– Currently, less than half of employers cover the expensive weight-loss medications.

– Even those that do cover them have guardrails in place that restrict access.

About 165 million Americans rely on employer-sponsored health insurance, and yet workers may still not get the coverage they want — particularly when it comes to drugs such as Novo Nordisk’s weight-loss drug Wegovy and diabetes drug Ozempic.

About 1 in 3 employees are looking for more resources to combat obesity, according to a recent report by consulting firm...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Employer, Healthcare System, Patient / Consumer, Pharma / Biotech, Pricing / Spending
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Stakeholder Management and Interoperability of Biosimilars
Anne Wojcicki has a new offer to take 23andMe private, this time for $74.7 million
Pharma Pulse 2/21/25: RWE in Medical Research and Drug Development, Inhaled Antibody Therapy for RSV & more
FDA approves first rapid-acting insulin biosimilar for diabetes

Share This Article